{
  "source": "PA-Non-Form-Exforge-HCT.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1243-7\nProgram Prior Authorization/Non-Formulary\nMedication Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT®*)\nP&T Approval Date 3/2018, 3/2019, 3/2020, 6/2021, 6/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nThe American College of Cardiology/American Heart Association Task Force recommends\ncombination pills rather than individual components to improve adherence to antihypertensive\ntherapy. This program allows for coverage of amlodipine/valsartan/hydrochlorothiazide (generic\nExforge HCT*), a triple antihypertensive therapy, for members who have not achieved an\nadequate response with the medications taken separately due to lack of adherence.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT*) will be\napproved based on both of the following:\na. Patient has a history of a trial resulting in a therapeutic failure (i.e. blood pressure\ngoal not met), to both of the following taken concomitantly:\ni. amlodipine/valsartan (generic Exforge)\nii. hydrochlorothiazide\n-AND-\nb. Patient is unable to adhere to antihypertensive therapy and prescriber determines\ncombination therapy would be beneficial.\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT*) will be\napproved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n*Brand Exforge HCT is typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on pr",
    "\n*Brand Exforge HCT is typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Whelton PK, Carey RM, Aronow WS, et al. 2017\nACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the\nprevention, detection, evaluation, and management of high blood pressure in adults: a report of\nthe American College of Cardiology/American Heart Association Task Force on Clinical Practice\nGuidelines. Hypertension. 2017\n2. Exforge HCT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July\n2023.\nProgram Prior Authorization/Non-Formulary –\nAmlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT)\nChange Control\n3/2018 New program.\n3/2019 Annual review. No changes.\n3/2020 Annual review. Updated references.\n6/2021 Formatting changes. Updated reference.\n6/2022 Annual review. Updated reference.\n10/2023 Annual review. Updated reference.\n10/2024 Annual review. No changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}